BioCentury | Apr 21, 2021
Finance

With upsized opportunity fund closing at €360M, Forbion readies to build on portfolio with three-pronged strategy

...in assets under managementTARGETSCETP – Cholesteryl ester transfer proteinCSF1R (C-FMS; CD115) Colony-stimulating factor 1 receptor Jeff Cranmer Forbion Capital Partners bee2021...
BioCentury | Mar 26, 2021
Finance

As valuation swells above $380M, Syncona-backed Gyroscope draws $148M series C, mulls listing

...could soon raise more via a U.S. listing.Forbion Capital Partners...
...I Paul Bonanos Gyroscope Therapeutics Ltd. (pre-merger) Syncona Ltd. Gyroscope Therapeutics Ltd. Forbion Capital Partners...
BioCentury | Mar 24, 2021
Emerging Company Profile

Dunad: Expanding protein degradation beyond E3 ligase

...in a series B round co-led by Forbion Capital Partners...
BioCentury | Mar 17, 2021
Finance

Forbion chooses Amphista as first protein degradation investment, co-leading $53M series B

...the landscape of targeted protein degradation companies, Forbion Capital Partners...
...Muellershausen will join Amphista’s board. Danielle Golovin Amphista Therapeutics Ltd. Forbion Capital Partners Gilde...
BioCentury | Feb 13, 2021
Deals

Feb. 12 Quick Takes: NexImmune, Decibel rise in NASDAQ debuts; plus Sagimet’s $80M crossover, Forbion launches VectorY, Aurora Science leads InteRNA round and a SPAC for Sharecare

...to have an initial enterprise value of $3.9 billion with about $400 million in capital. Jeff Cranmer Forbion Capital Partners InteRNA...
BioCentury | Dec 12, 2020
Finance

Forbion to focus record €460M fund on early-stage opportunities

...of the strategy of Forbion V,” said Forbion Capital Partners’...
...– NLR family pyrin domain containing 3 Virginia Li Forbion Capital Partners...
BioCentury | Sep 22, 2020
Deals

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

...products (see “BMS Expanding I-O Portfolio”).TARGETSNLRP3 (NALP3; CIAS1) – NLR family pyrin domain containing 3 Stephen Hansen Forbion Capital Partners Inflazome...
BioCentury | Jul 9, 2020
Finance

Forbion catering to abundance of maturing European biotechs with new growth fund

...Over” ; “Investing in Maturity” ; “Medicxi Unites Early, Late Stage Investing” ). Paul Bonanos, Associate Editor Forbion Capital Partners Forbion...
BioCentury | Mar 21, 2020
Product Development

Under duress, biotechs will have to make hard decisions for patients and themselves about which trials to run

...story. Targets AAT (A1AT; SERPINA1) - α-1 antitrypsin Karen Tkach Tuzman, Associate Editor Sofinnova Partners Synlogic Inc. Genenta Science s.r.l. Forbion Capital Partners Cerevance...
BioCentury | Feb 8, 2020
Finance

Forbion leads Azafaros’ €25M series A, with rare disease vet as chair

...within two years. Targets GBA2 - Non-lysosomal glucosylceramidase GCS - Glucosylceramide synthase Paul Bonanos, Associate Editor Azafaros B.V. Forbion Capital Partners Glucosidase...
Items per page:
1 - 10 of 178
BioCentury | Apr 21, 2021
Finance

With upsized opportunity fund closing at €360M, Forbion readies to build on portfolio with three-pronged strategy

...in assets under managementTARGETSCETP – Cholesteryl ester transfer proteinCSF1R (C-FMS; CD115) Colony-stimulating factor 1 receptor Jeff Cranmer Forbion Capital Partners bee2021...
BioCentury | Mar 26, 2021
Finance

As valuation swells above $380M, Syncona-backed Gyroscope draws $148M series C, mulls listing

...could soon raise more via a U.S. listing.Forbion Capital Partners...
...I Paul Bonanos Gyroscope Therapeutics Ltd. (pre-merger) Syncona Ltd. Gyroscope Therapeutics Ltd. Forbion Capital Partners...
BioCentury | Mar 24, 2021
Emerging Company Profile

Dunad: Expanding protein degradation beyond E3 ligase

...in a series B round co-led by Forbion Capital Partners...
BioCentury | Mar 17, 2021
Finance

Forbion chooses Amphista as first protein degradation investment, co-leading $53M series B

...the landscape of targeted protein degradation companies, Forbion Capital Partners...
...Muellershausen will join Amphista’s board. Danielle Golovin Amphista Therapeutics Ltd. Forbion Capital Partners Gilde...
BioCentury | Feb 13, 2021
Deals

Feb. 12 Quick Takes: NexImmune, Decibel rise in NASDAQ debuts; plus Sagimet’s $80M crossover, Forbion launches VectorY, Aurora Science leads InteRNA round and a SPAC for Sharecare

...to have an initial enterprise value of $3.9 billion with about $400 million in capital. Jeff Cranmer Forbion Capital Partners InteRNA...
BioCentury | Dec 12, 2020
Finance

Forbion to focus record €460M fund on early-stage opportunities

...of the strategy of Forbion V,” said Forbion Capital Partners’...
...– NLR family pyrin domain containing 3 Virginia Li Forbion Capital Partners...
BioCentury | Sep 22, 2020
Deals

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

...products (see “BMS Expanding I-O Portfolio”).TARGETSNLRP3 (NALP3; CIAS1) – NLR family pyrin domain containing 3 Stephen Hansen Forbion Capital Partners Inflazome...
BioCentury | Jul 9, 2020
Finance

Forbion catering to abundance of maturing European biotechs with new growth fund

...Over” ; “Investing in Maturity” ; “Medicxi Unites Early, Late Stage Investing” ). Paul Bonanos, Associate Editor Forbion Capital Partners Forbion...
BioCentury | Mar 21, 2020
Product Development

Under duress, biotechs will have to make hard decisions for patients and themselves about which trials to run

...story. Targets AAT (A1AT; SERPINA1) - α-1 antitrypsin Karen Tkach Tuzman, Associate Editor Sofinnova Partners Synlogic Inc. Genenta Science s.r.l. Forbion Capital Partners Cerevance...
BioCentury | Feb 8, 2020
Finance

Forbion leads Azafaros’ €25M series A, with rare disease vet as chair

...within two years. Targets GBA2 - Non-lysosomal glucosylceramidase GCS - Glucosylceramide synthase Paul Bonanos, Associate Editor Azafaros B.V. Forbion Capital Partners Glucosidase...
Items per page:
1 - 10 of 178